Time for New Guidelines in Handling of Neurodegenerative Disorders: Optimistic Versus Pessimistic Prognosis by Application of PPPM

Advances in Predictive, Preventive and Personalised Medicine

Volumn 3, Issue , 2013, Pages 3-9

  Mandel, Silvia ^a   Golubnitschaja, Olga ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Ageing; Early predictive diagnosis; Economy of personalised medicine; Healthcare industry; Neurosciences; Targeted preventive measures; Treatments tailored to the patient

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; TAU PROTEIN;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BLINDNESS; CEREBRAL PALSY; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DIABETIC RETINOPATHY; DRUG EFFICACY; ECONOMIC ASPECT; EPIGENETICS; EPILEPSY; GLAUCOMA; HEALTH CARE POLICY; HUMAN; INTEGRATIVE MEDICINE; MULTIPLE SCLEROSIS; NEUROPROTECTION; OXIDATIVE STRESS; PARASOMNIA; PARKINSON DISEASE; PERINATAL ASPHYXIA; PHYSICAL DISABILITY; POLYNEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RETINA MACULA AGE RELATED DEGENERATION; SCHIZOPHRENIA;

EID: 84927777076     PISSN: 22113495     EISSN: 22113509     Source Type: Book Series    
DOI: 10.1007/978-94-007-5866-7_1     Document Type: Article

References (21)

1. Golubnitschaja O (2010) Neurodegeneration: accelerated ageing or inadequate healthcare? EPMA J 1: 211-215.
2. Scarpa M (2011) Advanced healthcare for children and youth: application of targeted prevention, predictive diagnostics and personalised treatment approaches. EPMA J 2: 137-139.
3. Peeva V, Golubnitschaja O (2009) Birth asphyxia as the most frequent perinatal complication. In: Golubnitschaja O (ed) Predictive diagnostics and personalized treatment: dream or reality. Nova Science Publishers Inc, New York.
4. Yeghiazaryan K, Peeva V, Morelli M, Herrera-Marshitz M, Golubnitschaja O (2009) Potential targets for early diagnosis and neuroprotection in asphyxiated newborns. In: Golubnitschaja O (ed) Predictive diagnostics and personalized treatment: dream or reality. Nova Science Publishers Inc, New York.
5. Tounta G, Kolialexi A, Papantoniou N, Tsangaris G, Kanavakis E, Mavrou A (2011) Noninvasive prenatal diagnosis using cell-free fetal nucleic acids in maternal plasma: progress overview beyond predictive and personalized diagnosis. EPMA J 2: 163-171.
6. Tasker R, Adams-Marriott A, Shaw C (2010) New animal models of progressive neurodegeneration: tools for identifying targets in predictive diagnostics and presymptomatic treatment. EPMA J 1: 217-227.
7. Yeghiazaryan K, Flammer J, Orgül S, Wunderlich K, Golubnitschaja O (2009) Vasospastic individuals demonstrate significant similarity to glaucoma patients as revealed by gene expression profiling in circulating leukocytes. Mol Vis 15: 2339-2348.
8. Yeghiazaryan K, Flammer J, Golubnitschaja O (2010) Predictive molecular profiling in blood of healthy vasospastic individuals: clue to targeted prevention as personalised medicine to effective costs. EPMA J 1: 263-272.
9. Fulda S (2011) Idiopathic REM sleep behavior disorder as a long-term predictor of neurodegenerative disorders. EPMA J 2: 451-458.
10. Grossman I, Lutz M, Crenshaw D, Saunders A, Burns D, Roses A (2010) Alzheimer's disease: diagnostics, prognostics and the road to prevention. EPMA J 1: 293-303.
11. Mandel S, Morelli M, Halperin I, Korczyn A (2010) Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. EPMA J 1: 273-292.
12. Gozes I (2010) Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice. EPMA J 1: 305-316.
13. Grossman I, Miller A (2010) Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics. EPMA J 1: 317-327.
14. Döring A, Pfueller CF, Paul F, Dörr J (2011) Exercise in multiple sclerosis-an integral component of disease management. EPMA J 3: 2.
15. Nefussy B, Drory V (2010) Moving toward a predictive and personalized clinical approach in amyotrophic lateral sclerosis: novel developments and future directions in diagnosis, genetics, pathogenesis and therapies. EPMA J 1: 329-341.
16. Benkler C, Offen D, Melamed E, Kupershmidt L, Amit T, Mandel S, Youdim M, Weinreb O (2010) Recent advances in amyotrophic lateral sclerosis research: perspectives for personalized clinical application. EPMA J 1: 343-361.
17. Lagrange F (1922) Du glaucome et de l'hypotonie; leur traitement chirurgical. Doin, Paris.
18. Pache M, Flammer J (2006) A sick eye in a sick body? Systemic findings in patients with primary open-angle glaucoma. Surv Ophthalmol 51: 179-212.
19. Golubnitschaja O, Yeghiazaryan K, Flammer J (2010) Key molecular pathways affected by glaucoma pathology: is predictive diagnosis possible? EPMA J 1: 237-244.
20. Mozaffarieh M, Fraenkl S, Konieczka K, Flammer J (2010) Targeted preventive measures and advanced approaches in personalised treatment of glaucoma neuropathy. EPMA J 1: 229-235.
21. Hasler P, Flammer J (2010) Predictive, preventive and personalised medicine for age-related macular degeneration. EPMA J 1: 245-251.